TransCode RNAZ 深 沪
等待开盘 05-18 09:30:00 美东时间
6.60
-0.189
-2.78%
华盛通- 最 高7.22
- 今 开6.99
- 成交量 6379股
- 最 低 6.5601
- 昨 收 6.7886
- 总市值 605.20万
- 52周最高 20.99
- 市盈率 静 --
- 换手率 0.70%
- 52周最低 6.0829
- 委 比 2.44%
- 总股本 91.70万
- 历史最高 5174400.00
- 量 比 0.56
- 振 幅 9.72%
- 历史最低 6.1488
- 每 手 1
- 风险率 1.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多TransCode Therapeutics Q1 EPS $(21.28) Up From $(70.16) YoY
TransCode Therapeutics (NASDAQ:RNAZ) reported quarterly losses of $(21.28) per share. This is a 69.67 percent increase over losses of $(70.16) per share from the same period last year.
05-16 06:43
Transcode Therapeutics Files Prospecuts For Resale Of Up To 15,955,543 Shares By Selling Stockholders
TransCode Therapeutics, Inc.15,955,543 SharesCommon StockThis prospectus relates to the possible resale or other disposition from time to time by the selling stockholders named in this prospectus of up to an
05-01 05:35
美股夜盘 | FST Corp.涨47.54%，Kyverna Therapeutics, Inc.涨35.84%
FST Corp.涨47.54%；Kyverna Therapeutics, Inc.涨35.84%；Aspire Biopharma Holdings, Inc.涨18.85%
04-22 15:01
TransCode Therapeutics Enters Into Agreement With Institutional Healthcare Investor For Financing Of Up To $20M
TransCode Therapeutics, Inc. (NASDAQ:RNAZ, the ", Company", )), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an
04-07 20:37
TransCode Therapeutics Delays 2025 Annual Filing
TransCode Therapeutics ( ($RNAZ) ) has released a notification of late filing. ...
04-01 10:25
美股夜盘 | Urgent.ly Inc.涨160.10%，STRATS Trust for Allstate Corp Utd Sts Cellular Strats 6.375涨102.02%
Urgent.ly Inc.涨160.10%；STRATS Trust for Allstate Corp Utd Sts Cellular Strats 6.375涨102.02%；Click Holdings Limited Class A涨53.38%
03-16 09:02
TransCode Therapeutics Enters Into Exclusive, Worldwide, Fully Paid-Up Royalty-Free License Agreement With Unleash Immuno Oncolytics
TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer.BOSTON, March 3, 2026 /PRNewswire/
03-03 21:19
TransCode Therapeutics Secures Royalty-Free Worldwide License for Oncolytic Immunotherapy Candidates
TransCode Therapeutics Secures Royalty-Free Worldwide License for Oncolytic Immunotherapy Candidates TransCode Therapeutics Inc. said it entered an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc. to develop three drug candidates, UIO-524, UIO-5
03-03 21:03
TransCode Therapeutics licenses Unleash oncolytic immunotherapy platform in all-stock deal
TransCode Therapeutics licenses Unleash oncolytic immunotherapy platform in all-stock deal TransCode Therapeutics entered an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics for rights to develop and commercialize three oncolytic immunotherapy candida
03-03 21:01
TransCode Therapeutics Publishes Preclinical Results for Tumor-Selective RIG-I Immunotherapy Candidate
TransCode Therapeutics Publishes Preclinical Results for Tumor-Selective RIG-I Immunotherapy Candidate TransCode Therapeutics Inc. announced the publication of preclinical testing results for a tumor-selective RIG-I immunotherapeutic candidate in *Molecular Imaging and Biology*. The published study
02-23 21:03
